Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tango Therapeutics's Other Operating Expense for the
three
months ended in Mar. 2026 was $0.00 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.00 Mil.
Tango Therapeutics's quarterly Other Operating Expense
declined
from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil) but then
increased
from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($0.00 Mil).
Tango Therapeutics's annual Other Operating Expense
declined
from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($-0.00 Mil) but then
increased
from Dec. 2024 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil).
Tango Therapeutics Other Operating Expense Related Terms
Tango Therapeutics Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Tango Therapeutics's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of $-0.00 Mil mean?
Tango Therapeutics (TNGX) has a Other Operating Expense of $-0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Tango Therapeutics and its competitors.
Is Tango Therapeutics' Other Operating Expense too high?
Tango Therapeutics' current Other Operating Expense is $-0.00 Mil. Overall, Tango Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tango Therapeutics' Other Operating Expense compare to LEGN and CAI?
Tango Therapeutics' Other Operating Expense of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Tango Therapeutics and its competitors. Tango Therapeutics's current Other Operating Expense is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tango Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Tango Therapeutics (TNGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.92, compared to a current price of $27.67 — trading 178.9% above its estimated fair value. The current Other Operating Expense is $-0.00 Mil. Tango Therapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Tango Therapeutics (TNGX), the current Other Operating Expense is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tango Therapeutics (TNGX) Overvalued in 2026?
Based on GuruFocus' analysis, Tango Therapeutics stock appears to be overvalued.
The current stock price of $27.67 is trading 178.9% above its estimated GF Value™ of $9.92.
GuruFocus considers Tango Therapeutics to be Significantly Overvalued.
Key valuation signals for TNGX:
Other Operating Expense: $-0.00 Mil
GF Value™: $9.92 vs. price of $27.67 (178.9% above fair value)
No single metric tells the full story. See the TNGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
54GF Score
Get the complete analysis for TNGX
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNGX has been successfully added to your 
